Jasper Therapeutics, Inc. — Form 8-K
Filed October 15, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Jasper Therapeutics completed enrollment of 18 IgAN patients (6 each at Q2W, Q4W, Q8W maintenance doses) in its Phase 2 basket study of vensobafusp alfa (KP104) by October 15, 2026, on schedule. Interim Stage 1 data expected by year-end 2026. The company is accelerating a new FSGS expansion cohort with first patients dosed in Q1 2027. No financial figures, deal terms, or share issuances disclosed.
Why this rating
Clinical enrollment completion is routine Phase 2 progress. Positive for pipeline but no revenue impact. Relative to $74.8M market cap, no financing or M&A occurred. Execution on schedule is expected, not transformational.
See more from October 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.